Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Visionstate Announces Deals in Canada and the US, Highlights Growing Opportunities (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Verve Therapeutics Inc VERV

Healthcare Biotechnology
Verve Therapeutics, Inc. is a clinical-stage genetic medicines company. The Company is focused on developing a new approach to the care of cardiovascular disease (CVD), transforming treatment from chronic management to single-course gene editing medicines. The Company’s lead programs include VERVE-101, VERVE-102, and VERVE-201, which target genes that have been validated as targets for lowering... see more

Recent & Breaking News (NDAQ:VERV)

Kuehn Law Encourages Investors of Verve Therapeutics, Inc. to Contact Law Firm

Newsfile 9 hours ago

Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Accesswire 2 days ago

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 4 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Verve Therapeutics, Inc. (VERV) And Encourages Investors to Connect

Accesswire 5 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Verve Therapeutics, Inc. (VERV) And Encourages Stockholders to Connect

Accesswire 9 days ago

Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Accesswire 12 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Verve Therapeutics, Inc. (VERV) and Encourages Stockholders to Learn More About the Investigation

Accesswire December 22, 2024

Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Investors to Inquire about Securities Investigation

Accesswire December 18, 2024

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Verve Therapeutics, Inc. (VERV) And Encourages Investors to Reach Out

Accesswire December 15, 2024

VERV INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces an Investigation into Verve Therapeutics, Inc. and Encourages Investors to Contact the Firm

Accesswire December 13, 2024

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 29, 2024

Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial Results

GlobeNewswire November 5, 2024

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 1, 2024

Investors who lost money on Verve Therapeutics, Inc.(VERV) should contact Levi & Korsinsky about pending Class Action - VERV

Accesswire October 28, 2024

FINAL VERV DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Verve Therapeutics, Inc. Investors to Join the Class Action Lawsuit

Newsfile October 28, 2024

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics

Newsfile October 28, 2024

VERV LAWSUIT ALERT: Levi & Korsinsky Notifies Verve Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Accesswire October 28, 2024

VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit Filed by the Schall Law Firm

PR Newswire October 28, 2024

Verve Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VERV

PR Newswire October 28, 2024

Lost Money on Verve Therapeutics, Inc. (VERV)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

Accesswire October 28, 2024